Lagrue G, Hioco D, Kazandjian M, Cattaneo A, Cassagnol M
Sem Hop. 1980;56(21-24):1043-8.
Protected phosphate therapy was used in 65 cases of recurrent calcium nephrolithiasis. Mean duration treatment was 2 years and 1 month (more than 3 years in 17 cases). Mean lithiasis episodes by year-patients were 1,55 renal colics and 0.34 stone formation before phosphate treatment, versus 0.66 renal colics and 0.10 stone formation (more than 60% reduction), during treatment. There was simultaneously decrease of hypercalciuria (24 cases out of 42), of asthenia (16 cases out of 19), of signs of spasmophilia (12 cases out of 18) and disappearing of bone pains (4 cases out of 6). Side effects were rare. Minor digestive troubles were observed in 11 cases: diarrhea (3 cases) or gastralgias (9 cases). These side-effects necessitated discontinuation of thiazide therapy in only two cases and reduction of doses in 6 other cases. From our data, phosphate therapy appears an efficient drug in recurrent calcium nephrolithiasis. It acts in reducing levels of calciuria and enhancing urinary pyrophosphates excretion, inhibitors of calcium crystallization.
对65例复发性钙肾结石患者采用了保护性磷酸盐治疗。平均治疗时长为2年1个月（17例超过3年）。磷酸盐治疗前，患者每年平均结石发作次数为1.55次肾绞痛和0.34次结石形成，而治疗期间分别为0.66次肾绞痛和0.10次结石形成（减少超过60%）。同时，高钙尿症（42例中的24例）、乏力（19例中的16例）、抽搐倾向体征（18例中的12例）有所减轻，骨痛（6例中的4例）消失。副作用罕见。11例出现轻微消化系统问题：腹泻（3例）或胃痛（9例）。这些副作用仅导致2例停用噻嗪类疗法，6例减少剂量。根据我们的数据，磷酸盐治疗在复发性钙肾结石中似乎是一种有效的药物。它可降低尿钙水平并增加焦磷酸盐排泄，焦磷酸盐是钙结晶的抑制剂。
